An Open Label, Single Arm Trial to Evaluate Patients With Metastatic Renal Cell Carcinoma Treated With Everolimus After Failure of First Line Therapy With Sunitinib or Pazopanib.
Phase of Trial: Phase IV
Latest Information Update: 21 Jul 2017
At a glance
- Drugs Everolimus (Primary)
- Indications Renal cancer
- Focus Therapeutic Use
- Acronyms SUNPAZ
- Sponsors Novartis Pharmaceuticals
- 18 Feb 2017 Results presented at the 2017 Genitourinary Cancers Symposium
- 27 May 2016 Status changed from recruiting to completed as reported by European Clinical Trials Database record.
- 25 Mar 2014 Planned End Date changed from 1 Sep 2015 to 1 May 2016 as reported by ClinicalTrials.gov record.